Dexcom is pleased to announce the Food and Drug Administration (FDA) approval of the Dexcom G5 mobile app for Android devices. Beginning in June, Android users will have access to the free app for the Dexcom G5 Mobile CGM System, allowing people with diabetes to view and monitor their glucose levels on their mobile devices to manage their diabetes in real time. The Dexcom G5 Mobile CGM System is the first and only CGM platform available for Android in the United States, complementing the 2015 iOS launch.
Dexcom is pleased to announce that the U.S. Centers for Medicare & Medicaid Services (CMS) has published an article clarifying criteria for coverage and coding of the Dexcom G5 Mobile system, the only therapeutic CGM under this CMS classification. People covered by Medicare who have either Type 1 or Type 2 diabetes and intensively manage their insulin will now be able to obtain reimbursement.
EDINBURGH, Scotland, January 10, 2017 - DexCom, Inc. (NASDAQ:DXCM), the leader in Continuous Glucose Monitoring (CGM) for patients with diabetes, announced today that its G5 Mobile CGM System is now compatible on Android smart devices throughout Europe and South Africa. This new platform will be launching into select European countries today and continue throughout the fourth quarter of 2017.